Forskning ved Københavns Universitet - Københavns Universitet

Forside

Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity

Publikation: Bidrag til tidsskriftTidsskriftartikel

Standard

Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. / Dollerup, Ole L.; Trammell, Samuel A.J.; Hartmann, Bolette; Holst, Jens J.; Christensen, Britt; Møller, Niels; Gillum, Matthew P.; Treebak, Jonas T.; Jessen, Niels.

I: The Journal of clinical endocrinology and metabolism, Bind 104, Nr. 11, 01.11.2019, s. 5703-5714.

Publikation: Bidrag til tidsskriftTidsskriftartikel

Harvard

Dollerup, OL, Trammell, SAJ, Hartmann, B, Holst, JJ, Christensen, B, Møller, N, Gillum, MP, Treebak, JT & Jessen, N 2019, 'Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity', The Journal of clinical endocrinology and metabolism, bind 104, nr. 11, s. 5703-5714. https://doi.org/10.1210/jc.2019-01081

APA

Dollerup, O. L., Trammell, S. A. J., Hartmann, B., Holst, J. J., Christensen, B., Møller, N., ... Jessen, N. (2019). Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. The Journal of clinical endocrinology and metabolism, 104(11), 5703-5714. https://doi.org/10.1210/jc.2019-01081

Vancouver

Dollerup OL, Trammell SAJ, Hartmann B, Holst JJ, Christensen B, Møller N o.a. Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. The Journal of clinical endocrinology and metabolism. 2019 nov 1;104(11):5703-5714. https://doi.org/10.1210/jc.2019-01081

Author

Dollerup, Ole L. ; Trammell, Samuel A.J. ; Hartmann, Bolette ; Holst, Jens J. ; Christensen, Britt ; Møller, Niels ; Gillum, Matthew P. ; Treebak, Jonas T. ; Jessen, Niels. / Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. I: The Journal of clinical endocrinology and metabolism. 2019 ; Bind 104, Nr. 11. s. 5703-5714.

Bibtex

@article{a7c167bb2ea84bbaa401f0740f3c5c1e,
title = "Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity",
abstract = "OBJECTIVE: Augmenting nicotinamide adenine dinucleotide (NAD+) metabolism through dietary provision of NAD+ precursor vitamins translates to improved glucose handling in rodent models of obesity and diabetes. Preclinical evidence suggests that the NAD+/SIRT1 axis may be implicated in modulating important gut-related aspects of glucose regulation. We sought to test whether NAD+ precursor supplementation with nicotinamide riboside (NR) affects β-cell function, α-cell function, and incretin hormone secretion as well as circulating bile acid levels in humans. DESIGN: A 12-week randomized, double-blind, placebo-controlled, parallel-group trial in 40 males with obesity and insulin resistance allocated to NR at 1000 mg twice daily (n = 20) or placebo (n = 20). Two-hour 75-g oral glucose tolerance tests were performed before and after the intervention, and plasma concentrations of glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were determined. β-Cell function indices were calculated based on glucose, insulin, and C-peptide measurements. Fasting plasma concentrations of bile acids were determined. RESULTS: NR supplementation during 12 weeks did not affect fasting or postglucose challenge concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. Additionally, no changes in circulating adipsin or bile acids were observed following NR supplementation. CONCLUSION: The current study does not provide evidence to support that dietary supplementation with the NAD+ precursor NR serves to impact glucose tolerance, β-cell secretory capacity, α-cell function, and incretin hormone secretion in nondiabetic males with obesity. Moreover, bile acid levels in plasma did not change in response to NR supplementation.",
author = "Dollerup, {Ole L.} and Trammell, {Samuel A.J.} and Bolette Hartmann and Holst, {Jens J.} and Britt Christensen and Niels M{\o}ller and Gillum, {Matthew P.} and Treebak, {Jonas T.} and Niels Jessen",
year = "2019",
month = "11",
day = "1",
doi = "10.1210/jc.2019-01081",
language = "English",
volume = "104",
pages = "5703--5714",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "11",

}

RIS

TY - JOUR

T1 - Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity

AU - Dollerup, Ole L.

AU - Trammell, Samuel A.J.

AU - Hartmann, Bolette

AU - Holst, Jens J.

AU - Christensen, Britt

AU - Møller, Niels

AU - Gillum, Matthew P.

AU - Treebak, Jonas T.

AU - Jessen, Niels

PY - 2019/11/1

Y1 - 2019/11/1

N2 - OBJECTIVE: Augmenting nicotinamide adenine dinucleotide (NAD+) metabolism through dietary provision of NAD+ precursor vitamins translates to improved glucose handling in rodent models of obesity and diabetes. Preclinical evidence suggests that the NAD+/SIRT1 axis may be implicated in modulating important gut-related aspects of glucose regulation. We sought to test whether NAD+ precursor supplementation with nicotinamide riboside (NR) affects β-cell function, α-cell function, and incretin hormone secretion as well as circulating bile acid levels in humans. DESIGN: A 12-week randomized, double-blind, placebo-controlled, parallel-group trial in 40 males with obesity and insulin resistance allocated to NR at 1000 mg twice daily (n = 20) or placebo (n = 20). Two-hour 75-g oral glucose tolerance tests were performed before and after the intervention, and plasma concentrations of glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were determined. β-Cell function indices were calculated based on glucose, insulin, and C-peptide measurements. Fasting plasma concentrations of bile acids were determined. RESULTS: NR supplementation during 12 weeks did not affect fasting or postglucose challenge concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. Additionally, no changes in circulating adipsin or bile acids were observed following NR supplementation. CONCLUSION: The current study does not provide evidence to support that dietary supplementation with the NAD+ precursor NR serves to impact glucose tolerance, β-cell secretory capacity, α-cell function, and incretin hormone secretion in nondiabetic males with obesity. Moreover, bile acid levels in plasma did not change in response to NR supplementation.

AB - OBJECTIVE: Augmenting nicotinamide adenine dinucleotide (NAD+) metabolism through dietary provision of NAD+ precursor vitamins translates to improved glucose handling in rodent models of obesity and diabetes. Preclinical evidence suggests that the NAD+/SIRT1 axis may be implicated in modulating important gut-related aspects of glucose regulation. We sought to test whether NAD+ precursor supplementation with nicotinamide riboside (NR) affects β-cell function, α-cell function, and incretin hormone secretion as well as circulating bile acid levels in humans. DESIGN: A 12-week randomized, double-blind, placebo-controlled, parallel-group trial in 40 males with obesity and insulin resistance allocated to NR at 1000 mg twice daily (n = 20) or placebo (n = 20). Two-hour 75-g oral glucose tolerance tests were performed before and after the intervention, and plasma concentrations of glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were determined. β-Cell function indices were calculated based on glucose, insulin, and C-peptide measurements. Fasting plasma concentrations of bile acids were determined. RESULTS: NR supplementation during 12 weeks did not affect fasting or postglucose challenge concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. Additionally, no changes in circulating adipsin or bile acids were observed following NR supplementation. CONCLUSION: The current study does not provide evidence to support that dietary supplementation with the NAD+ precursor NR serves to impact glucose tolerance, β-cell secretory capacity, α-cell function, and incretin hormone secretion in nondiabetic males with obesity. Moreover, bile acid levels in plasma did not change in response to NR supplementation.

UR - http://www.scopus.com/inward/record.url?scp=85073183847&partnerID=8YFLogxK

U2 - 10.1210/jc.2019-01081

DO - 10.1210/jc.2019-01081

M3 - Journal article

C2 - 31390002

AN - SCOPUS:85073183847

VL - 104

SP - 5703

EP - 5714

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -

ID: 231301319